Observational studyDrug safety2018
Osteoporosis-Related Fractures in HIV-Infected Patients Receiving Long-Term Tenofovir Disoproxil Fumarate: An Observational Cohort Study.
Observational study in Drug safety, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- People with HIV infection had lower bone mineral density and increased fracture risk: a meta-analysis.Archives of osteoporosis · 2021Pooled it
- Screening for bone health in older people with HIV: Uptake and outcomes from a large UK outpatient HIV service.HIV medicine · 2026Article
- Clinical insights into the association between chronic liver disease and osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Review
- Development and internal validation of a diagnostic prediction model for osteoporosis in elderly people living with HIV receiving antiretroviral therapy: a cross-sectional study.BMC infectious diseases · 2026Article
- Premature Skeletal Aging and Immunological Recovery in Romanian PLWH: A Cross-Sectional Analysis of Gender-Specific and Metabolic Risk Factors.International journal of molecular sciences · 2026Article
- Low Bone Mineral Density in Men Living with HIV on Tenofovir Antiretroviral Therapy: A Cross-Sectional Exploratory Study from a Malaysian Tertiary Hospital.Tropical medicine and infectious disease · 2026Article
- Longitudinal changes in bone mineral density among children living with HIV over 96 weeks following switch to second-line antiretroviral therapy in Uganda.PLOS global public health · 2026Article
- Linking the relationship between drug-induced osteoporosis and the gut microbiota.Frontiers in endocrinology · 2026Review
- Bilateral Pathological Femoral Fractures Secondary to Long-Term Tenofovir Disoproxil Fumarate-Induced Osteomalacia in a Woman Living with HIV: A Case Report.International medical case reports journal · 2026Article
- Article
- Prevalence of metabolic diseases in patients infected with HIV receiving antiretroviral therapy at Sultan Qaboos University Hospital, Oman.IJID regions · 2025Article
- Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Article
- Evaluation of Bone Mineral Density and Related Factors in Romanian HIV-Positive Patients Undergoing Antiretroviral Therapy.Microorganisms · 2025Article
- Immunosenescence and its related comorbidities in older people living with HIV.Infectious diseases & immunity · 2025Review
- Evaluation of serum phosphorus levels and their relation with the development of osteoporosis in people living with HIV/AIDS.Revista da Associacao Medica Brasileira (1992) · 2025Article
- Effect of Oral Bisphosphonates on Vertebral Fractures in Males Living with HIV: A Seven Year Study.Journal of clinical medicine · 2024Article
- Prevalence of and risk factors for vertebral fracture and low bone mineral density among Peruvian women aging with HIV.Archives of osteoporosis · 2023Article
- Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.Annals of internal medicine · 2022Article
- Sex Differences in Non-AIDS Comorbidities Among People With Human Immunodeficiency Virus.Open forum infectious diseases · 2021Review
- Longitudinal change in bone mineral density among Chinese individuals with HIV after initiation of antiretroviral therapy.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with HIV infection may have a higher prevalence of osteoporosis and osteopenia, as well as an increased risk of bone fracture compared with non-HIV-infected individuals. Antiretroviral therapy is thought to be one of factors associated to osteoporosis-related bone fractures.
objectiveThe aim of this study was to assess the effects of long-term exposure to tenofovir disoproxil fumarate (TDF) on the cumulative risk of osteoporosis-related bone fractures in Japanese patients with HIV infection.
designThis observational cohort study comprised a joint HIV-related drug survey of patients treated with TDF between April 2004 and March 2013.
methodsThirty-five healthcare facilities in Japan participated in the survey. The incidence of osteoporosis-related fractures was extracted from all adverse events (AEs) using standardized Medical Dictionary for Regulatory Activities queries, and used to calculate the fracture rate per 10,000 patient-years (PY). Kaplan-Meier analysis was used to estimate the cumulative probability of fracture during the study period.
resultsA total of 3251 patients who received TDF or TDF/emtricitabine between April 2004 and March 2013 were analyzed in this study; 93.5% of patients were male. The fracture rate was 13.5 per 10,000 PY in males and 42.2 per 10,000 PY in females. The mean age for male patients with osteoporosis-related fracture was 43.2 years, whereas it was 65.7 years in female patients. The cumulative probability of osteoporosis-related fracture increased after ≥ 5 years of TDF exposure. The rate of hip fracture (95% confidence interval) was 7.2 (3.1-14.2) per 10,000 PY.
conclusionsAmong HIV-infected patients in Japan, treatment with TDF for ≥ 5 years increases the risk of bone fractures in younger men, in addition to that seen in older post-menopausal women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.